Eaton Vance Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Eaton Vance Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$5.21M	Buy	61,432 +551	+0.9%	+$49.1K	0.01%	773
2022 Q2	$5.04M	Sell	60,881 -19,925	-25%	-$1.59M	0.01%	806
2022 Q1	$6.23M	Buy	80,806 +62,834	+350%	+$5.26M	0.01%	825
2021 Q4	$1.59M	Sell	17,972 -3	-0%	-$248	﹤0.01%	1076
2021 Q3	$1.34M	Sell	17,975 -126	-0.7%	-$9.94K	﹤0.01%	1015
2021 Q2	$1.51M	Buy	18,101 +86	+0.5%	+$6.82K	﹤0.01%	1072
2021 Q1	$1.36M	Sell	18,015 -3	-0%	-$245	﹤0.01%	1064
2020 Q4	$1.58M	Buy	18,018 +566	+3%	+$44.9K	﹤0.01%	978
2020 Q3	$1.33M	Sell	17,452 -75,552	-81%	-$7.64M	﹤0.01%	930
2020 Q2	$11.5M	Sell	93,004 -10,108	-10%	-$1M	0.02%	424
2020 Q1	$8.71M	Buy	103,112 +135	+0.1%	+$11.6K	0.02%	437
2019 Q4	$8.71M	Sell	102,977 -2,497	-2%	-$189K	0.02%	485
2019 Q3	$7.11M	Sell	105,474 -87	-0.1%	-$6.7K	0.02%	520
2019 Q2	$9.04M	Sell	105,561 -20,483	-16%	-$1.75M	0.02%	449
2019 Q1	$11.2M	Sell	126,044 -25,582	-17%	-$2.37M	0.03%	391
2018 Q4	$12.9M	Sell	151,626 -942	-0.6%	-$89.6K	0.03%	318
2018 Q3	$14.8M	Sell	152,568 -19,820	-11%	-$1.98M	0.03%	334
2018 Q2	$16.2M	Sell	172,388 -204,690	-54%	-$17.9M	0.04%	306
2018 Q1	$30.6M	Sell	377,078 -34,157	-8%	-$2.93M	0.04%	314
2017 Q4	$36.7M	Sell	411,235 -70,817	-15%	-$6.16M	0.09%	203
2017 Q3	$44.9M	Buy	482,052 +1,893	+0.4%	+$167K	0.12%	164
2017 Q2	$43.6M	Sell	480,159 -75,631	-14%	-$6.88M	0.11%	175
2017 Q1	$48.8M	Sell	555,790 -12,009	-2%	-$1.07M	0.13%	163
2016 Q4	$47M	Buy	567,799 +244,181	+75%	+$21M	0.13%	165
2016 Q3	$29.9M	Sell	323,618 -91,256	-22%	-$8.59M	0.09%	184
2016 Q2	$32.3M	Buy	414,874 +364,780	+728%	+$31M	0.09%	179
2016 Q1	$4.13M	Buy	50,094 +452	+0.9%	+$36.8K	0.01%	433
2015 Q4	$5.2M	Sell	49,642 -769	-2%	-$80.3K	0.02%	397
2015 Q3	$5.31M	Buy	50,411 +36,411	+260%	+$4.86M	0.02%	393
2015 Q2	$1.92M	Hold	14,000	–	–	0.01%	538
2015 Q1	$1.75M	Buy	+14,000	New	+$1.48M	0.01%	584

Other funds holding BMRN

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Eaton Vance Management's BMRN Position: Q3 2022 in Review

Eaton Vance Management increased its BioMarin Pharmaceuticals (BMRN) stake by 0.91% in Q3 2022, buying an estimated $49.1K and bringing the position to 61,432 shares worth $5.21M. The position accounts for 0.01% of the portfolio, ranked #773.

Eaton Vance Management first reported a position in BMRN in Q1 2015 and has held it in 31 quarters since. The position peaked at $48.8M in Q1 2017. 551 funds tracked by Wall St. Rank hold BMRN as of Q3 2022.

Eaton Vance Management held 61,432 shares of BioMarin Pharmaceuticals worth $5.21M as of Q3 2022.
Eaton Vance Management bought 551 BioMarin Pharmaceuticals shares in Q3 2022, an estimated $49.1K.
BioMarin Pharmaceuticals made up 0.01% of Eaton Vance Management's portfolio in Q3 2022, its #773 holding.
Eaton Vance Management first reported a position in BioMarin Pharmaceuticals in Q1 2015 and has held it in 31 quarters since.
Eaton Vance Management's BioMarin Pharmaceuticals position peaked at $48.8M in Q1 2017.
551 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2022.

Based on Eaton Vance Management's 13F filing for Q3 2022, filed 14 Nov 2022.